2015 American Transplant Congress
Predictors of Time to Recurrence and Mortality Associated With Recurrent Hepatocellular Carcinoma After Liver Transplantation
Transplantation, UCLA, Los Angeles, CA.
Background: While recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) portends a poor prognosis, adjuvant therapy may prolong survival. We sought to identify factors that…2015 American Transplant Congress
Clinical Impact of 18F-FDG-PET/CT in Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma
Liver Cancer Center, National Cancer Center, Goyang, Korea.
Background: The relevant number of patients with hepatocellular carcinoma (HCC) beyond the Milan criteria has undergone living donor liver transplantation (LDLT). However, the prognostic factors…2015 American Transplant Congress
Adoptive Immunotherapy With Liver Allograft-Derived NK Cells Improves Recurrence-Free Survival After Living-Donor Liver Transplantation in Patients With Hepatocellular Carcinoma
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan.
Introduction: Previous studies revealed that the recurrence rate of hepatocellular carcinoma (HCC) was still 10–20%, even among liver transplantation (LT) recipients meeting the Milan criteria…2015 American Transplant Congress
Liver Transplantation for Hepatocellular Carcinoma inside Milan Criteria: Lower Recurrence in Patients With Hepatitis C Infection
Mayo Clinic, Jacksonville, FL.
Purpose: Hepatitis C infection (HCV) related-cirrhosis can lead to hepatocellular carcinoma (HCC). Liver transplantation (LT) is the optimal treatment for selected patients with HCC, providing…2015 American Transplant Congress
Split and Living Donor Versus Whole Liver Transplantation for Hepatocellular Carcinoma in Adult Recipients: A Single Center Analysis
Liver Transplant Unit, Edouard Herriot Hospital, lyon, France.
INTRODUCTIONThe use of partial liver grafts in the context of hepatocellular carcinoma (HCC) remains a matter ofdebate because of a supposed higher risk of cancer…2015 American Transplant Congress
Association Between Polymorphisms of PPM1E Gene and Tumor Size of Hepatocellular Carcinoma Patients
The protein phosphatase, Mg2+/Mn2+ dependent, 1E (PPM1E) inactivates multiple substrates including 5'-AMP activate protein kinases (AMPK) which inhibits the growth and survival of cancer cells.…2015 American Transplant Congress
Grip Strength, Gait Speed, and Chair Stands Predict Sarcopenia in Male But Not Female Liver Transplant Candidates
University of California, San Francisco, San Francisco, CA.
Background: Sarcopenia, as determined by cross-sectional skeletal muscle index (SMI), is associated with waitlist mortality in liver transplant (LT) candidates, but has limited clinical utility…2015 American Transplant Congress
Recurrence of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) Alone and TACE in Combination With Other Treatment Modalities
General Surgery, Houston Methodist Hospital, Houston, TX.
AIM:Treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) can help downstage tumors prior to orthotopic liver transplantation (OLT); however, there is a risk of…2015 American Transplant Congress
Early Detection of HCC Mutations in Indeterminate Lesions Using Liquid Biopsies
Background Recent sequencing efforts have characterized the mutation profile of hepatocellular carcinoma (HCC); however, the relevance to clinical decision-making has been limited by the infrequency…2015 American Transplant Congress
Long-Term Outcome After Liver Transplantation for Unresectable Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment
Background: Liver transplantation remains the only curative treatment option for patients with unresectable hepatocellular carcinoma (HCC). Several bridging treatments are employed because the limited availability…
American Transplant Congress abstracts